Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...
Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...
Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...
The chart below compares the forward price to earnings (P/E) ratio of AstraZeneca to multiples in a peer set of leading ...
Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...
Diane Brady: Leadership Next is powered by the folks at Deloitte who, like me, are exploring the changing roles of business ...
Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...
In the United Kingdom, the government is hoping weight loss drugs might improve public finances, eyeing their use to help ...
A Goldman Sachs economist has suggested that the US economy could experience accelerated growth with increased use of GLP-1 ...
Nov 13 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of weekly injections. The results ...
Al Jazeera on MSN2d
Could weight loss drugs fix UK’s unemployment problem?The United Kingdom will study whether the use of weight loss drugs could get people back to work. UK Health Minister Wes ...
clinicaltrialsarena on MSN3d
Lilly reports trial results of tirzepatide for treating obesity and pre-diabetesEli Lilly has reported comprehensive outcomes from the SURMOUNT-1 study of tirzepatide for treating pre-diabetic and obese ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback